pSivida Corp. (PSDV) announced its licensee, Alimera Sciences, reported the submission of its response to the second Complete Response Letter from FDA with respect to ILUVIEN for chronic diabetic macular edema. Alimera submitted the response, which includes additional analyses of the risks and benefits of ILUVIEN based on the clinical data available from the previously completed Phase III studies, following a meeting with the FDA in the second quarter 2012.
If the FDA approves ILUVIEN, pSivida would be entitled to a $25 million milestone payment as well as 20% of net profits, on any sales in the U.S. by Alimera.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.